§8731. Definitions As used in this subchapter, unless the context otherwise indicates, the following terms have the following meanings. [PL 2019, c. 470, §8 (NEW).] 1. Brand-name drug. “Brand-name drug” means a prescription drug marketed under a proprietary name or registered trademark name, including a biological product. [PL 2019, c. 470, §8 (NEW).] […]
§8732. Drug price notifications and disclosures 1. Notifications by manufacturers. [PL 2021, c. 305, §4 (AMD); MRSA T. 22 §8732, sub-§1 (RP).] 1-A. Public notice of substantial drug price change or introduction. No later than January 30, 2022 and annually thereafter, the organization shall produce and post on its publicly accessible website a list of […]
§8733. Confidentiality Information provided to the organization as required by this subchapter by a manufacturer, wholesale drug distributor or pharmacy benefits manager is confidential and not a public record under Title 1, chapter 13, except that the organization may share information: [PL 2019, c. 470, §8 (NEW).] 1. Bureau of Insurance. With the Department […]
§8734. Registration requirements Beginning January 1, 2020, manufacturers, wholesale drug distributors and pharmacy benefits managers subject to this subchapter shall register annually with the organization in a manner prescribed by the organization. [PL 2021, c. 305, §8 (AMD).] SECTION HISTORY PL 2019, c. 470, §8 (NEW). PL 2021, c. 305, §8 (AMD).
§8735. Compliance 1. Certification of accuracy. A manufacturer, wholesale drug distributor or pharmacy benefits manager that submits a notification or report to the organization pursuant to this subchapter shall submit with the notification or report a signed written certification of the notification’s or report’s accuracy. [PL 2019, c. 470, §8 (NEW).] 2. Civil penalty. […]
§8736. Public report Beginning November 1, 2020 and annually thereafter, the organization shall produce and post on its publicly accessible website an annual report, including information developed from the disclosures received pursuant to this subchapter on trends in the cost of prescription drugs, analysis of manufacturer prices and price increases, the major components of prescription […]
§8737. Rulemaking The organization may adopt rules to implement this subchapter. Rules adopted pursuant to this section are major substantive rules as defined in Title 5, chapter 375, subchapter 2‑A. [PL 2019, c. 470, §8 (NEW).] SECTION HISTORY PL 2019, c. 470, §8 (NEW).
